NRG-103

DRUG2 trials

Sponsors

Zhongnan Hospital, Neuregen Therapeutics Co., Ltd.

Conditions

Glioblastoma (GBM)HGGHigh Grade GliomaHigh Grade Glioma (III or IV)

Early Phase 1

Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients

RecruitingNCT06757153

Zhongnan HospitalGlioblastoma (GBM)

Start: 2024-12-19End: 2027-12-31Target: 15Updated: 2025-01-03

Phase 1

A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

RecruitingNCT07710690

Neuregen Therapeutics Co., Ltd.HGG, High Grade Glioma, High Grade Glioma (III or IV)

Start: 2026-07-09End: 2030-04-30Target: 24Updated: 2026-07-17